Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis
IntroductionThis meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with Helicobacter pylori (H. pylori) infection.Materials and methodsFour databases (PubMed, Embase, Web of Scien...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmicb.2025.1561749/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850219723999936512 |
|---|---|
| author | Xiao Li Cheng Jiang Yuwen Su Ruiyun Gao Peijun Yang Yuechen Qin Yue Zou Weiming Liang Jieru Quan Liying Pan |
| author_facet | Xiao Li Cheng Jiang Yuwen Su Ruiyun Gao Peijun Yang Yuechen Qin Yue Zou Weiming Liang Jieru Quan Liying Pan |
| author_sort | Xiao Li |
| collection | DOAJ |
| description | IntroductionThis meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with Helicobacter pylori (H. pylori) infection.Materials and methodsFour databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched published from establishment of database to June 1, 2024, for articles studying VA dual therapy compared to BQT for patients with H. pylori infection. Meta-analyses of eradication rates, adverse events, compliance and cost were preformed.ResultsA total of 17 studies were included for meta-analysis. Compared with BQT, VA increased the incidence of H. pylori eradication rate, with significant difference under the ITT analysis (86.9% vs. 80.4%, RR = 1.07, 95% CI: 1.01–1.12, p = 0.01) but there no significant difference under the PP analysis (90.7% vs. 86.5%, RR = 1.03, 95% CI: 0.99–1.08, p = 0.13). Besides, VA significantly increased compliance (RR = 1.03, 95% CI: 1.01–1.05, p < 0.01) and decreased the occurrence of total adverse events (27.0% vs. 11.5%, RR = 0.43, 95% CI: 0.37–0.51, p < 0.01). Furthermore, VA has lower cost compared to BQT.ConclusionOur findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with H. pylori infection.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738, identifier CRD42024576738 (PROSPERO). |
| format | Article |
| id | doaj-art-85f1bf73543e4b36adda52ac239a42f9 |
| institution | OA Journals |
| issn | 1664-302X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Microbiology |
| spelling | doaj-art-85f1bf73543e4b36adda52ac239a42f92025-08-20T02:07:17ZengFrontiers Media S.A.Frontiers in Microbiology1664-302X2025-03-011610.3389/fmicb.2025.15617491561749Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysisXiao Li0Cheng Jiang1Yuwen Su2Ruiyun Gao3Peijun Yang4Yuechen Qin5Yue Zou6Weiming Liang7Jieru Quan8Liying Pan9The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaLingui Campus, Guilin Medical University, Guilin, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaSchool of Economics and Management, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaIntroductionThis meta-analysis aims to compare the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy in comparison to bismuth-containing quadruple therapy (BQT) for patients with Helicobacter pylori (H. pylori) infection.Materials and methodsFour databases (PubMed, Embase, Web of Science, and Cochrane Library) were searched published from establishment of database to June 1, 2024, for articles studying VA dual therapy compared to BQT for patients with H. pylori infection. Meta-analyses of eradication rates, adverse events, compliance and cost were preformed.ResultsA total of 17 studies were included for meta-analysis. Compared with BQT, VA increased the incidence of H. pylori eradication rate, with significant difference under the ITT analysis (86.9% vs. 80.4%, RR = 1.07, 95% CI: 1.01–1.12, p = 0.01) but there no significant difference under the PP analysis (90.7% vs. 86.5%, RR = 1.03, 95% CI: 0.99–1.08, p = 0.13). Besides, VA significantly increased compliance (RR = 1.03, 95% CI: 1.01–1.05, p < 0.01) and decreased the occurrence of total adverse events (27.0% vs. 11.5%, RR = 0.43, 95% CI: 0.37–0.51, p < 0.01). Furthermore, VA has lower cost compared to BQT.ConclusionOur findings indicated that VA dual therapy provided a higher eradication rate, enhanced compliance, decreased adverse events, and lowered cost relative to BQT for patients with H. pylori infection.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024576738, identifier CRD42024576738 (PROSPERO).https://www.frontiersin.org/articles/10.3389/fmicb.2025.1561749/fullH. pyloriamoxicillinvonoprazaneradicationbismuth-containing quadruple therapycompliance |
| spellingShingle | Xiao Li Cheng Jiang Yuwen Su Ruiyun Gao Peijun Yang Yuechen Qin Yue Zou Weiming Liang Jieru Quan Liying Pan Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis Frontiers in Microbiology H. pylori amoxicillin vonoprazan eradication bismuth-containing quadruple therapy compliance |
| title | Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis |
| title_full | Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis |
| title_fullStr | Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis |
| title_full_unstemmed | Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis |
| title_short | Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis |
| title_sort | efficacy and safety of vonoprazan amoxicillin dual therapy versus bismuth containing quadruple therapy for patients with helicobacter pylori infection a meta analysis |
| topic | H. pylori amoxicillin vonoprazan eradication bismuth-containing quadruple therapy compliance |
| url | https://www.frontiersin.org/articles/10.3389/fmicb.2025.1561749/full |
| work_keys_str_mv | AT xiaoli efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT chengjiang efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT yuwensu efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT ruiyungao efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT peijunyang efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT yuechenqin efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT yuezou efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT weimingliang efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT jieruquan efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis AT liyingpan efficacyandsafetyofvonoprazanamoxicillindualtherapyversusbismuthcontainingquadrupletherapyforpatientswithhelicobacterpyloriinfectionametaanalysis |